

Ramsay Health Care Limited

# Results Briefing

Half Year ended 31 December 2017

Craig McNally, Managing Director

28 February 2018

# AGENDA

1. Group Operational and Financial Highlights
2. Segment Operational and Financial Highlights
3. Growth Strategy Update
4. Outlook

# Group Financial & Operational Highlights

# GROUP HALF YEAR FINANCIAL HIGHLIGHTS

- Core NPAT up 7.5% to \$288.0 million
- Core EPS up 7.8% to 139.0 cents
- Group:
  - Revenue up 3.0% to \$4.4 billion
  - EBIT up 1.5% to \$470.4 million
- Australia/Asia:
  - Australia Revenue up 4.3% to \$2.5 billion
  - Australia EBIT up 9.1% to \$379.7 million
  - Equity accounted share of Asia JV net profits up 24.1% to \$8.5 million
- United Kingdom:
  - Revenue down 4.8% to £206.2 million
  - EBITDAR down 4.6% to £49.4 million
- France:
  - Revenue down 1.1% to €1.1 billion
  - EBITDAR down 5.8% to €194.1 million
- Interim Dividend 57.5 cents fully franked, up 8.5%

# HALF YEAR OPERATIONAL HIGHLIGHTS

## Australian operations performed well

- Delivered 9.1% EBIT growth on the previous corresponding period as a result of above market volume growth and the ongoing benefits of cost efficiency programmes
- Government reforms announced in the period, which aim to improve affordability of private health insurance in Australia, will overall, impact positively on the industry

## Ongoing challenging operating environment in UK / France

- In Europe, our operations held up well in an environment that is currently experiencing pricing constraints and volume pressures
- RGdS achieved above market volume growth thanks to strength of portfolio and diversity of our business in France
- Investing in a major transformation project in our French operations that will centralise non-core hospital resources and distinguish this business for the long term
- A positive tariff adjustment will take affect from 1 April 2018 in the UK however, NHS demand management strategies are currently impacting volumes significantly

## Continuing investment in growth initiatives

- During the period a further \$146M in hospital capacity expansions were approved by the Board
- \$57M worth of brownfields were completed late in first half of FY18. \$147M worth of developments will open in second half of FY18 and a further \$156M in first half of FY19
- 23 pharmacies were added to the Ramsay Pharmacy Franchise Network in Australia (including 18 Malouf stores in December) bringing total number in the Network to 54

# Group Financial Overview

Bruce Soden, Finance Director

# GROUP FINANCIAL PERFORMANCE

Six months ended 31 December	2017 \$m	2016 \$m	Increase
Revenue	4,445.8	4,317.6	3.0%
EBITDAR	872.5	841.1	3.7%
EBITDA	663.8	648.9	2.3%
EBIT	470.4	463.5	1.5%
<b>Core NPAT attributable to members of the parent <sup>(1)</sup></b>	<b>288.0</b>	<b>267.8</b>	<b>7.5%</b>
<b>Core EPS <sup>(2)</sup> (cents per share)</b>	<b>139.0¢</b>	<b>128.9¢</b>	<b>7.8%</b>
Interim Dividend – fully franked (cents per share)	57.5¢	53.0¢	8.5%

Strong Australian operations / Challenges remain in France and UK

**Notes:**

All numbers are in Australian dollars unless otherwise stated

<sup>(1)</sup> Core NPAT attributable to members of the parent is before non-core items. The minority interests share of Ramsay Générale de Santé Core NPAT has been removed in arriving at Core NPAT attributable to members of the parent

<sup>(2)</sup> Core EPS is derived from core net profit after CARES dividends




# RECONCILIATION TO STATUTORY PROFIT

Six months ended 31 December	2017 \$m	2016 \$m	Increase/ Decrease
Core NPAT	288.0	267.8	7.5%
Net Non-core Items net of tax <sup>(1)</sup>			
• Restructuring charge RGdS	(23.9)	-	
• Other	(17.6)	(11.9)	
	<b>(41.5)</b>	<b>(11.9)</b>	
<b>Reported Statutory Net Profit after tax attributable to members of the Parent</b>	<b>246.5</b>	<b>255.9</b>	<b>(3.7%)</b>

<sup>(1)</sup> Net non-core items (net of tax)			2017 \$m	2016 \$m
	UK & Australia	France	Group	Group
Non-cash portion of rent relating to UK hospitals	(7.3)	-	(7.3)	(8.0)
Amortisation – service concession assets	(2.0)	-	(2.0)	(1.7)
Restructuring, acquisition, disposal, impairment, development costs, and profit/(loss) on disposal of non-current assets	(11.9)	(62.6)	(74.5)	14.8
Borrowing costs associated with refinancing	(0.4)	-	(0.4)	(11.7)
	(21.6)	(62.6)	(84.2)	(6.6)
Income tax on non-core items	2.8	18.0	20.8	5.2
Non-controlling interest in non-core items	-	21.9	21.9	(10.5)
<b>Net non-core items (net of tax) attributable to members of the Parent</b>	<b>(18.8)</b>	<b>(22.7)</b>	<b>(41.5)</b>	<b>(11.9)</b>




# CORE NPAT AND CORE EPS



- Core NPAT up 7.5% to \$288.0 million
- Core EPS up 7.8% to 139.0 cents


# DIVIDEND GROWTH



- Strong, consistent growth in dividends
- Interim dividend fully franked, up 8.5% on previous corresponding interim dividend, more than matching the 7.8% increase Core EPS
- Intention to maintain full year dividend payout ratio of approximately 50% of Core EPS, balance reinvested into the business

# LEVERAGE AND CASH MANAGEMENT

## Consolidated Balance Sheet Leverage Ratio



- Strong operating cash flow with high cash conversion rate
- Strong balance sheet with financial flexibility to continue to fund:
  - the pipeline of brownfield capacity expansion
  - future acquisitions

# Segment Operational and Financial Highlights

# FINANCIAL HIGHLIGHTS – AUSTRALIA & ASIA

Six Months ended 31 December	2017 \$m	2016 \$m	Increase
<b><u>AUSTRALIA</u></b> <sup>(1)</sup>			
Revenue	2,483.9	2,382.2	4.3%
EBITDAR	486.4	444.3	9.5%
EBITDA	458.5	422.3	8.6%
EBIT	379.7	348.1	9.1%
<sup>(1)</sup> The above figures include Head Office			
EBIT Margin (%)	15.3%	14.6%	+ 67 bps
<b><u>ASIA</u></b>			
Equity accounted share of net profits of joint venture	8.5	6.9	24.1%

## **Australia:**

- Continued growth in admissions and procedural volumes in Ramsay's Australian business during the period
- Operational efficiencies continue to drive margin improvement due to cost restructuring programme implemented over last 2 years

## **Asia:**

- Strong operational performance in Malaysia and Indonesia

# OPERATING ENVIRONMENT - AUSTRALIA



## Current Operating Environment



Reduction in PHI membership but increasing demand in key market demographic – the over 65s



Private patients in public hospitals - unsustainable



Recent focus on private healthcare and improving value and affordability will impact positively overall



Stable reimbursement environment with majority of funding arrangements negotiated in FY17 with multiyear terms

## Operational Outlook




Volume growth continues to be driven by an ageing population rise in chronic disease and a growing mental health burden



Non-hospital earnings growth opportunities emerging

# FINANCIAL HIGHLIGHTS - FRANCE



## Operating Highlights



Revenue down 1.1% to €1.1 billion  
EBITDAR down 5.8% to €194.1 million



Overall admissions growth, and strong cost management substantially mitigated the negative tariff setting

## Operational Outlook



March 2018 decrease in tariff lower than anticipated




Significant centralisation programme underway in France – 3 year programme with annual recurring gains to RGdS estimated at €5M once fully implemented.



Patient transport business continues to grow with new assets acquired during the period



# FINANCIAL HIGHLIGHTS – UNITED KINGDOM



## Operating Highlights



Revenue down 4.8% to £206.2 million  
EBITDAR down 4.6% to £49.4 million



NHS demand management strategies significantly impacting volumes.

## Operational Outlook



Positive tariff adjustment will take effect from 1 April 2018 in the UK



Burgeoning number of people waiting for treatment in the UK. Expect normal volume growth will return in the short to medium term

# Growth Strategy

# ATTRACTIVE & DIVERSIFIED ASSET PORTFOLIO



# GLOBAL INDUSTRY FUNDAMENTALS



The number of people aged over **65** has increased to more than **656 million**, or **11.5%** of the total population



Globally, the number of people with diabetes is expected to rise from the current **415 million** to **642 million by 2040**



Depression is the leading cause of ill health and disability worldwide. More than **300 million** people are now living with depression, an increase of more than **18%** between 2005 and 2015

- In all regions, health spending is rising as populations grow and age, technologies improve and patients become better informed
- Demand for health care is going to rise faster than the capacity of the sector itself

# DELIVERING ON OUR GROWTH STRATEGY

Continuing to create shareholder value through our focused strategy



## ORGANIC GROWTH

Underpinned by demographics, quality portfolio of hospitals, ongoing business improvement and volume expansion.



## BROWNFIELD CAPACITY EXPANSION

Local market knowledge drives business cases. We build capacity aimed at satisfying unmet demand. Apply strong financial discipline.



## PUBLIC/PRIVATE COLLABORATIONS

Global focus on increasing private sector role in service provision for publicly funded patients.



## ACQUISITIONS

Exploring acquisitions in existing and new markets. Ramsay has proven it can export its management model. Must add long-term value to shareholders.



## INTEGRATED CARE

Opportunities arising to supplement our core strategy by developing and delivering integrated care to patients across an increasingly disperse health ecosystem.

# DEVELOPMENTS

During 1H FY18 the Board approved the following capacity expansions and investments:



**\$146M**  
projects



**167** beds



**11** operating  
theatres



**23** retail  
pharmacy  
franchises



# BROWNFIELD DEVELOPMENTS

## Expansions underway

- Albert Road Clinic (48 beds)
- Northside Clinic at St Leonards (gross 112; net 24 beds)
- Lake Macquarie (30 beds)
- Additional theatres/catheter laboratories at North Shore, Westmead, St George, Sunshine Coast, Baringa and Peninsula Private Hospitals
- St Andrew's Ipswich Private Hospital (81 beds, 2 theatres, plus new private ED)
- Warners Bay (39 beds)
- Northside Macarthur (14 beds)
- Major consulting suite developments at John Flynn (21 suites) and Greenslopes (30 suites)
- Tees Valley - UK (18 beds, 1 theatre)

## Approved in 1H 2018 - \$146M

- Beleura Private (46 beds)
- John Flynn (12 day oncology chairs)
- Hollywood Private (4 theatres)
- West Midlands UK (1 theatre)
- North Shore Private (4 theatres)
- Peninsula (70 beds, 2 theatres)
- Westmead Private (39 beds)

## Pipeline

- **\$147M** due to open 2H FY18
- **\$156M** due to open 1H FY19
- **Over \$500M** in business cases under consideration (inc major expansion of Joondalup Health Campus)



*St Andrews Ipswich Hospital Expansion  
(artist impression)*



*The New Northside St Leonards Clinic  
(artist impression)*



# PHARMACY

- Ramsay Pharmacy franchise network is expanding – now 54 pharmacies
- Slower than expected expansion due to regulatory delays
- In December 2017, Ramsay added Queensland's 18 Malouf pharmacies to its Franchise network. Malouf was the largest privately owned pharmacy group in Queensland
- Flagship store opened in Melbourne CBD – Jan 2018
- Concentrating on sites close to hospitals so patients can benefit from receiving both medication and other integrated care services beyond the hospital walls
- Includes 4 x 24/7 community pharmacies in our major hospitals



# Outlook



# Outlook

- Attractive demographic sector fundamentals combined with Ramsay's geographic, casemix and reimbursement diversification as well as a consistent execution of Company strategy, will underpin our future growth.
- In addition to brownfield development growth, we remain acquisitive and are actively investigating opportunities across all markets.
- As the demand for healthcare rises in both traditional and non-traditional settings, we continue to investigate out-of-hospital opportunities where we can deliver innovative, cost-effective and patient-centred care to the community.
- Ramsay's scale and diversity will ensure it continues to deliver earnings growth in an ever-changing health economy.
- Strategic investments are being made in research and technology as well as shaping our workforce to ensure we remain at the forefront of healthcare delivery in the future.
- We expect the operating environment in Australia to remain positive and the environment in Europe to remain challenging. Barring unforeseen circumstances, we reaffirm our FY18 Core EPS growth of 8% to 10%.



People caring for people



# Questions